Evaluation of dysfunctional high‐density lipoprotein levels with myeloperoxidase/paraoxonase‐1 ratio in rheumatoid arthritis. Issue 7 (29th March 2021)

• Record Type: Journal Article
• Authors: Alisik, Tugba; Alisik, Murat; Nacir, Baris; Ayhan, Fikriye Figen; Genc, Hakan; Erel, Ozcan
• Is Part Of: International journal of clinical practice. Volume 75:Issue 7(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-29
• Subjects: Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.14172
• Languages: English
• ISSNs: 1368-5031

Abstract

Abstract: Background: The aim of this study is to evaluate dysfunctional high‐density lipoprotein cholesterol (HDL) by measuring myeloperoxidase (MPO)/paraoxonase 1 (PON1) ratio in patients with rheumatoid arthritis (RA) and to investigate the relationship between dysfunctional HDL and cardiovascular disease (CVD) in RA patients. Methods: Sixty‐seven healthy individuals and 130 RA patients were included in the study. Routine lipid panels (triglyceride (TG), low‐density lipoprotein cholesterol (LDL), HDL, total cholesterol (TC), PON1 and MPO levels were measured. Disease activity scores‐28 (DAS28) of RA patients were calculated. Cardiological examination records of the patients were assessed to detect patients who also have CVD. Results: There were no significant differences between RA and control groups in routine lipid profiles ( P > .05 for all). MPO/PON1 ratios were significantly elevated in the RA group compared with the control group ( P < .001). MPO/PON1 ratios were higher in RA patients with CVD history compared with those without CVD ( P < .05). MPO/PON1 ratios were correlated with DAS28 scores (rho: 0.357, P < .001). Conclusion: HDL dysfunction determined by the MPO/PON1 ratio may be associated with the pathophysiology of increased CVD in RA. Thus, evaluating dysfunctional HDL levels by measuring the MPO/PON1 ratio in RA patients may allow more detailed patient follow‐up, as well as the reduction of CVD events in RA patients with therapeutic agents aiming to increase the functional properties of HDL by decreasing this ratio.